INTRAORAL PLEOMORPHIC ADENOMA: A CLINICOPATHOLOGIC STUDY OF A CASE SERIES

Author(s):  
MARIA EDUARDA PÉREZ-DE-OLIVEIRA ◽  
AUGUSTO CÉSAR LEAL DA SILVA LEONEL ◽  
ELAINE JUDITE DE AMORIM CARVALHO ◽  
JUREMA FREIRE LISBOA DE CASTRO ◽  
KAMILLA KARLA MAURÍCIO PASSOS ◽  
...  
2006 ◽  
Vol 35 (7) ◽  
pp. 608-612 ◽  
Author(s):  
M. Ethunandan ◽  
R. Witton ◽  
G. Hoffman ◽  
A. Spedding ◽  
P.A. Brennan

2015 ◽  
Vol 5 (5) ◽  
pp. 460-468 ◽  
Author(s):  
Edward C. Kuan ◽  
Miguel Fernando Palma Diaz ◽  
Alexander G. Chiu ◽  
Marvin Bergsneider ◽  
Marilene B. Wang ◽  
...  

2017 ◽  
Vol 126 (7) ◽  
pp. 544-547 ◽  
Author(s):  
Molly Naunheim ◽  
Xin Wu ◽  
William R. Ryan ◽  
Steven J. Wang ◽  
Chase M. Heaton

Objectives: Surgery for recurrent pleomorphic adenoma (PA) can be challenging and may increase the risk of operative complications, particularly facial nerve weakness. As observation may be a viable alternative to surgery for slow-growing tumors, our objective was to assess the growth rate of recurrent PAs. Study Design: This study is a case series of patients at our tertiary academic medical center with recurrent PA. Two magnetic resonance images (MRI) were compared; total volume (TV) of recurrent tumor on both studies was calculated to obtain our main outcomes of percent change in TV and tumor growth rate. Results: Fourteen patients with recurrent PA had a median interval time between MRI of 12.8 months. Though growth rates were variable, the median continuous compound growth per year was 10.2%. Notably, 3 patients (21%) had no growth, and 2 patients (14%) had a reduction in TV. Conclusions: The median growth rate for enlarging tumors is estimated at 10.2% per year. Due to variability, tumor growth rate should be estimated on an individual patient basis. For slow-growing tumors, physicians may weigh the risk of this slow growth with the morbidity of reoperation.


2020 ◽  
Vol 7 (3) ◽  
pp. 900
Author(s):  
M. S. Kalyan Kumar ◽  
R. Shyamsundar ◽  
M. Sabari Girieasen ◽  
R. Kannan ◽  
S. Nedunchezhiyan

Pleomorphic adenoma is the most common tumor of the benign salivary gland neoplasms, the submandibular gland is the second most common site of PA after the parotid gland. Authors present 3 series case of pleomorphic adenoma in submandibular salivary gland in institution which were admitted in institution within a month interval. Fine needle aspiration cytology (FNAC) of all 3 cases proved to be benign lesion arising from submandibular salivary gland. All 3 cases underwent excision in to and the postoperative period was uneventful. DT removed on 3rd POD and discharged in POD 10. Biopsy report proved to be pleomorphic adenoma in all cases. past studies showed pleomorphic adenoma most commonly occurs in the parotid gland and its occurrence in the submandibular salivary gland is uncommon. Also, age occurrence involves 30s-50s and is more common in females. But all this case was male and occurred in older age group. Early intervention with surgical excision in toto after definite confirmation with FNAC is the treatment of choice in preventing its malignant transformation.


2021 ◽  
Vol 28 (7) ◽  
pp. 983-986
Author(s):  
Muhammad Arham ◽  
◽  
Jahangir Sarwar Khan ◽  
Muhammad Arish ◽  
Naveed Akhtar Malik ◽  
...  

Objective: To determine surgical complications and recurrence rate in patients with benign lesions of the parotid undergoing extracapsular dissection. Study Design: Case Series. Setting: Department of Surgery, Rawalpindi Medical University, Rawalpindi. Period: January 2010 and December 2018. Material & Methods: The hospital records of all 50 patients who underwent extracapsular dissection with a diagnosis of either Pleomorphic adenoma or War thin tumor between reviewed retrospectively. Data regarding demographics, tumor, complications and recurrence was collected. Results: Out of 50 patients, 40 were males and 10 were females with age ranging from 26 to 52 years and mean age of 42 years. 44 of 50 parotid lumps were diagnosed as Pleomorphic adenoma and 6 were cases of Warthin tumor. The range of lesion size was 1.5 to 3 cm. 15 (30%) patients suffered from transient facial nerve weakness, whereas only 1 (2%) sustained a facial nerve injury which required repair. There was no case of Frey syndrome, sialocele and hematoma, however, salivary fistula was seen in 1 (2%) patient. Capsule rupture during surgery occurred in 15 (30%) patients and recurrence was seen in only 1 patient (2%). Conclusion: Extracapsular dissection has low recurrence rate, very few complications and is a safe and effective treatment for Pleomorphic adenoma and Warthin tumor.


2017 ◽  
Vol 52 (1) ◽  
pp. e7-e9 ◽  
Author(s):  
Neelam Pushker ◽  
Seema Kashyap ◽  
Seema Sen ◽  
Mandeep S. Bajaj ◽  
Maya Hada

2012 ◽  
Vol 136 (1) ◽  
pp. 61-75 ◽  
Author(s):  
Rachel J Shakked ◽  
David S Geller ◽  
Richard Gorlick ◽  
Howard D Dorfman

Context.—Mesenchymal chondrosarcoma is a rare, high-grade malignancy of bone or soft tissue with a unique, biphasic histology and poor prognosis. Because of its rarity and variable length of disease-free survival, the natural history of the disease remains poorly understood. Objective.—To present clinical, radiographic, and histopathologic features of mesenchymal chondrosarcoma from one of the largest case series collected by a single, senior-level bone pathologist. Design.—Twenty cases were reviewed in consultations spanning 45 years. Results.—Eighteen tumors (90%) originated in bone, and 2 tumors (10%) were of extraskeletal origin. Of the skeletal tumors, locations included craniofacial bones (n  =  9; 50%), ribs and chest wall (n  =  4; 22%), sacrum and spinal elements (n  =  3; 17%), and lower extremities (n  =  2; 11%), whereas soft tissue tumors were located about the scapula (n  =  1; 50%) and lower extremity (n  =  1; 50%). Plain radiographs demonstrated calcified, osteolytic lesions with extraosseous extension. Typical histologic features were identified consisting of small, round or spindled cells, interspersed with hyaline cartilage islands. Seventeen patients (85%) were treated surgically, and 8 patients (40%) received adjuvant treatment. Seven patients (35%) were living at last follow-up, 1.8 to 12.5 years after diagnosis, and 8 patients (40%) died between 1.2 and 21.8 years after diagnosis. Conclusions.—Mesenchymal chondrosarcoma presents multiple challenges. Diagnostic pitfalls include inadequate biopsy samples, which may result in sample error. Sox9 has been proposed as a unique marker for mesenchymal chondrosarcoma which may improve diagnostic specificity. Treatment and prognosis vary considerably. Patients who receive surgery and chemotherapy seem to fare better. Multicenter studies with higher sample numbers may improve our understanding of this malignancy.


Sign in / Sign up

Export Citation Format

Share Document